Company / Cash & Equivalents
PUMA BIOTECHNOLOGY, INC. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$29.6M
FY2025
5-year range
$29.6M / $84.6M
FY2021-FY2025
Trend
-57.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $30M in FY2025 to $108M in FY2018.
Based on SEC 10-K filings.
$30M in FY2025 with a 5-year CAGR of -19.1%.
Declined from $85M to $30M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -27.0%
- 5-Year CAGR
- -19.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -19.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 57.2% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.6M | -57.2% |
| FY2024 | $69.2M | -18.2% |
| FY2023 | $84.6M | +11.0% |
| FY2022 | $76.2M | +20.7% |
| FY2021 | $63.1M | -26.0% |
| FY2020 | $85.3M | +42.1% |
| FY2019 | $60.0M | -44.6% |
| FY2018 | $108.4M | +32.7% |
| FY2017 | $81.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026